This finding was supported by our previous report on xenograft models of Nalm6 leukemia, in which CD3/CD28 Dynabead T cells proliferated earlier and to a greater extent than did OKT3/IL-2 T cells, resulting in better disease control. This evidence concerns the gene CD28 and leukemia.